IL245287A0 - Preparations for oral administration of zoledronic acid - Google Patents

Preparations for oral administration of zoledronic acid

Info

Publication number
IL245287A0
IL245287A0 IL245287A IL24528716A IL245287A0 IL 245287 A0 IL245287 A0 IL 245287A0 IL 245287 A IL245287 A IL 245287A IL 24528716 A IL24528716 A IL 24528716A IL 245287 A0 IL245287 A0 IL 245287A0
Authority
IL
Israel
Prior art keywords
compositions
oral administration
related compounds
zoledronic acid
treating disease
Prior art date
Application number
IL245287A
Other languages
English (en)
Hebrew (he)
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Herriot Tabuteau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/063,979 external-priority patent/US8802658B2/en
Application filed by Antecip Bioventures Ii Llc, Herriot Tabuteau filed Critical Antecip Bioventures Ii Llc
Publication of IL245287A0 publication Critical patent/IL245287A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL245287A 2013-10-25 2016-04-21 Preparations for oral administration of zoledronic acid IL245287A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/063,979 US8802658B2 (en) 2012-05-14 2013-10-25 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/279,241 US20140249317A1 (en) 2012-05-14 2014-05-15 Compositions for oral administration of zoledronic acid or related compounds for treating disease
PCT/US2014/050427 WO2015060924A1 (en) 2013-10-25 2014-08-08 Compositions for oral administration of zoledronic acid or related compounds for treating disease

Publications (1)

Publication Number Publication Date
IL245287A0 true IL245287A0 (en) 2016-06-30

Family

ID=52993341

Family Applications (2)

Application Number Title Priority Date Filing Date
IL245287A IL245287A0 (en) 2013-10-25 2016-04-21 Preparations for oral administration of zoledronic acid
IL254123A IL254123A0 (en) 2013-10-25 2017-08-23 Preparations for oral administration of zoledronic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL254123A IL254123A0 (en) 2013-10-25 2017-08-23 Preparations for oral administration of zoledronic acid

Country Status (12)

Country Link
EP (1) EP3060220A4 (ja)
JP (6) JP6166471B2 (ja)
KR (3) KR20190009428A (ja)
CN (2) CN105960240B (ja)
AU (2) AU2014340649C1 (ja)
CA (1) CA2928350C (ja)
HK (1) HK1257400A1 (ja)
IL (2) IL245287A0 (ja)
MX (1) MX2016005396A (ja)
MY (1) MY176246A (ja)
SG (3) SG11201603042TA (ja)
WO (1) WO2015060924A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
KR20190009428A (ko) * 2013-10-25 2019-01-28 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
WO2018079763A1 (ja) 2016-10-28 2018-05-03 三菱ケミカル株式会社 炭素繊維用サイジング剤、炭素繊維用サイジング剤の水分散液、及びサイジング剤付着炭素繊維束

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1057488A4 (en) * 1998-12-25 2003-10-22 Toray Industries INTERLEUKIN-6 PRODUCTION INHIBITORS
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
HUP0400096A2 (hu) * 2001-05-02 2004-04-28 Novartis Ag. Biszfoszfonátok gyógyászati alkalmazása
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
JP2006506365A (ja) * 2002-10-15 2006-02-23 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの投与方法
WO2005005447A2 (en) * 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
AR046773A1 (es) * 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
CA2769633C (en) * 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
HUE035744T2 (en) * 2010-02-06 2018-05-28 Gruenenthal Gmbh Crystallization process and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2013173330A1 (en) * 2012-05-14 2013-11-21 Antecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
KR20190009428A (ko) * 2013-10-25 2019-01-28 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물

Also Published As

Publication number Publication date
CA2928350C (en) 2018-01-09
JP2021028343A (ja) 2021-02-25
KR20170058444A (ko) 2017-05-26
JP6166471B2 (ja) 2017-07-19
KR101975687B1 (ko) 2019-05-07
KR20190009428A (ko) 2019-01-28
CA2928350A1 (en) 2015-04-30
JP2017200941A (ja) 2017-11-09
JP2022162105A (ja) 2022-10-21
MY176246A (en) 2020-07-24
MX2016005396A (es) 2017-03-01
CN108434154A (zh) 2018-08-24
KR101739244B1 (ko) 2017-05-23
SG10201609548UA (en) 2016-12-29
KR20160062177A (ko) 2016-06-01
SG11201603042TA (en) 2016-05-30
JP6453387B2 (ja) 2019-01-16
AU2014340649C1 (en) 2017-05-18
JP6802245B2 (ja) 2020-12-16
JP7136487B2 (ja) 2022-09-13
EP3060220A4 (en) 2017-05-31
CN105960240A (zh) 2016-09-21
EP3060220A1 (en) 2016-08-31
AU2017200832A1 (en) 2017-03-02
JP2024040304A (ja) 2024-03-25
IL254123A0 (en) 2017-10-31
JP2019059771A (ja) 2019-04-18
CN105960240B (zh) 2018-04-20
AU2014340649B2 (en) 2016-11-17
WO2015060924A1 (en) 2015-04-30
JP2016534081A (ja) 2016-11-04
SG10201800001VA (en) 2018-02-27
HK1257400A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
HK1257400A1 (zh) 用於治療疾病的唑來膦酸或相關化合物的經口施用組合物
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
ME03042B (me) Jedinjenja i kompozicije za tretman parazitskih oboljenja
HK1217443A1 (zh) 用於糖尿病的口服治療的藥物組合物
EP2968321A4 (en) COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES
HRP20190349T1 (hr) Oralni pripravci za liječenje gastroezofagealne refluksne bolesti
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
IL238592B (en) Compounds for the treatment of liver diseases
ZA201508452B (en) Oral formulation for the treatment of cardiovascular diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HUE037176T2 (hu) Olaj-alapú gyógyszerészeti készítmény gasztrointesztinális betegségek kezelésére
EP2854539A4 (en) PHOSPHONATE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB201407847D0 (en) Composition for the oral delivery of compounds
IL240119A0 (en) Pharmaceutical compositions for oral treatment of diabetes